Company Description
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform.
In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting.
It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC.
The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.
ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Country | United States |
| Founded | 1998 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 172 |
| CEO | Joseph Burnett |
Contact Details
Address: 120 S. Sierra Avenue, Suite 100 Solana Beach, California 92075 United States | |
| Phone | 888 287 9109 |
| Website | clearpointneuro.com |
Stock Details
| Ticker Symbol | CLPT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1285550 |
| CUSIP Number | 18507C103 |
| ISIN Number | US18507C1036 |
| Employer ID | 58-2394628 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Joseph Michael Burnett | President, Chief Executive Officer and Director |
| Danilo D'Alessandro | Chief Financial Officer |
| Jeremy L. Stigall | Chief Business Officer |
| Mazin Sabra | Chief Operating Officer |
| Ellisa Cholapranee J.D. | General Counsel and Secretary |
| Dr. Paul S. Larson FAANS, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2026 | 10-K | Annual Report |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 13, 2026 | SCHEDULE 13G | Filing |
| Feb 25, 2026 | 144 | Filing |
| Feb 20, 2026 | 144/A | Filing |
| Feb 9, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 5, 2026 | 8-K/A | [Amend] Current report |
| Feb 5, 2026 | D | Notice of Exempt Offering of Securities |
| Feb 4, 2026 | SCHEDULE 13G/A | Filing |
| Jan 26, 2026 | 144 | Filing |